A dual activity, conjugated approach has been taken to form hybrid molecules of two known antimalarial
drugs, chloroquine (CQ) and the non-sedating H1 antagonist astemizole. A variety of linkers were investigated
to conjugate the two agents into one molecule. Compounds 5–8 possessed improved in vitro
activity against a CQ-resistant strain of Plasmodium falciparum, and examples 7 and 8 were active
in vivo in mouse models of malaria.